Valeant To Acquire Obagi Medical

Valeant To Acquire Obagi

Valeant Pharmaceuticals International has entered into a definitive agreement to acquire Obagi Medical Products. Under the terms of the agreement, Valeant will acquire all of the outstanding common stock of Obagi Medical Products for $19.75 per share in cash. The transaction is expected to close in the first half of 2013.
Obagi Medical Products is a leader in topical aesthetic and therapeutic skin-health systems with a product portfolio that includes leading dermatology brands including Obagi Nu-Derm, Condition & Enhance, Obagi-C Rx, ELASTIDerm and CLENZIDerm.
“The acquisition of Obagi will be a valuable supplement to Valeant’s current dermatology portfolio and will further build upon our growing aesthetics franchise,” said J. Michael Pearson, chairman and CEO of Valeant. “Obagi is a leader in the physician-dispensed market and enjoys a strong brand perception among physicians. The addition of their products will not only strengthen and diversify our dispensed portfolio, but also expand our market presence with dermatologists and plastic surgeons."

More in News